Clinical trialNCT05732103RecruitingPhase 1/PHASE2Interventional

A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

SponsorChordia Therapeutics, Inc.Enrollment225Acute Myeloid LeukemiaMyelodysplastic Syndromes

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Guillermo Garcia-Manero, MD
M.D. Anderson Cancer Center
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Mayo Clinic Arizona
Phoenix, Arizona, United States
Cecilia A Yi, MD, MSHS
Recruiting
Mayo Clinic Florida
Jacksonville, Florida, United States
James Foran, MD
Recruiting
Northwestern University
Chicago, Illinois, United States
Jessica Altman, MD
Recruiting
Mayo Clinic Comprehensive Cancer Center
Rochester, Minnesota, United States
Antoine Saliba, MD
Recruiting
the University of Rochester
Rochester, New York, United States
Jason Mendler, MD, PhD
Recruiting
the University of Texas Md Anderson Cancer Center
Houston, Texas, United States
Guillermo Garcia-Manero, MD →
Recruiting
University of Virginia
Charlottesville, Virginia, United States
Daniel Reed, MD
Recruiting
Fred Hutchinson Cancer Center
Seattle, Washington, United States
Anna Halpern, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Rogocekib

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 25 Apr 2023
Primary completion: 30 Jun 2028
Completion: 28 Feb 2029
Last update posted: 13 Apr 2026
Registered enrollment: 225
Registry id: NCT05732103

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.